Adaptimmune (ADAP) Down on End of Collaboration With Roche

15.04.24 20:12 Uhr

Werte in diesem Artikel
Aktien

233,40 CHF -1,00 CHF -0,43%

Indizes

1.246,4 PKT -2,0 PKT -0,16%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

14.102,4 PKT -51,1 PKT -0,36%

1.954,6 PKT -0,6 PKT -0,03%

11.983,6 PKT -17,9 PKT -0,15%

1.645,4 PKT -2,7 PKT -0,17%

15.970,4 PKT -26,4 PKT -0,17%

3.546,5 PKT -0,7 PKT -0,02%

4.510,7 PKT -19,2 PKT -0,42%

15.836,0 PKT -26,1 PKT -0,16%

6.919,4 PKT 41,6 PKT 0,60%

Adaptimmune Therapeutics plc ADAP announced that its strategic collaboration with Roche’s RHHBY Genentech has been terminated. Shares of ADAP were down 10% on the news.Both companies collaborated in 2021 to develop and commercialize allogeneic cell therapies to treat multiple oncology indications.The collaboration had two components — the development of allogeneic T-cell therapies for up to five shared cancer targets and the development of personalized allogeneic T-cell therapies.ADAP was responsible for developing clinical candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells). Roche was responsible for the input TCRs and subsequent clinical development and commercialization.Adaptimmune received an upfront payment of $150 million and was entitled to additional payments of $150 million over five years, along with milestone payments exceeding $3 billion in aggregate value.The loss of funds from Roche is a setback for ADAP and its investors were clearly disappointed.Shares of Adaptimmune have risen 46.3% year to date against the industry’s decline of 7.9%.Image Source: Zacks Investment ResearchNevertheless, management believes in the long-term potential of its iPSC-based allogeneic platform and remains focused on launching the first product in its sarcoma franchise, afami-cel, pending approval. Adaptimmune is preparing to launch the first product in its sarcoma franchise, afami-cel, for the treatment of advanced synovial sarcoma, pending review and approval from the FDA. The regulatory body has set a target action date of Aug 4, 2024.Per the company, afami-cel would be the first engineered T-cell therapy (for treating solid tumors) to receive commercial approval in the United States.Adaptimmune's second product in its sarcoma franchise, lete-cel, is being investigated in the IGNYTE-ESO study (NCT03967223).Lete-cel, an engineered TCR T-cell therapy targeting the solid tumor antigen NY-ESO-1, was originally developed by Adaptimmune, and further developed under a collaboration and license agreement with GSK plc GSK.In 2023, Adaptimmune and GSK agreed on terms regarding the return of the NY-ESO program back to the former.Meanwhile, Roche also has a collaboration agreement with a clinical-stage cell and gene therapy company Poseida Therapeutics, Inc. PSTX.Poseida continues to develop allogeneic CAR-T therapies targeting hematological malignancies in partnership with Roche. Poseida has plans to continue the development of P-BCMA-ALLO1 in 2024, in partnership with Roche, for the treatment of relapsed/refractory multiple myeloma.Adaptimmune currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.It’s an American AI company that’s riding low right now, but it has rounded up clients like BMW, GE, Dell Computer, and Bosch. It has prospects for not just doubling but quadrupling in the year to come. Of course, all our picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Poseida Therapeutics, Inc. (PSTX): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf On

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf On

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Roche AG (Genussschein)

Analysen zu Roche AG (Genussschein)

DatumRatingAnalyst
17.05.2024Roche NeutralUBS AG
17.05.2024Roche HoldDeutsche Bank AG
16.05.2024Roche UnderweightJP Morgan Chase & Co.
16.05.2024Roche HoldJefferies & Company Inc.
14.05.2024Roche NeutralUBS AG
DatumRatingAnalyst
24.04.2024Roche KaufenDZ BANK
24.04.2024Roche OutperformBernstein Research
02.02.2024Roche KaufenDZ BANK
19.10.2023Roche KaufenDZ BANK
29.08.2023Roche BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
17.05.2024Roche NeutralUBS AG
17.05.2024Roche HoldDeutsche Bank AG
16.05.2024Roche HoldJefferies & Company Inc.
14.05.2024Roche NeutralUBS AG
06.05.2024Roche NeutralUBS AG
DatumRatingAnalyst
16.05.2024Roche UnderweightJP Morgan Chase & Co.
24.04.2024Roche UnderweightJP Morgan Chase & Co.
15.04.2024Roche UnderweightJP Morgan Chase & Co.
12.04.2024Roche UnderweightJP Morgan Chase & Co.
05.04.2024Roche UnderweightJP Morgan Chase & Co.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Roche AG (Genussschein) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"